Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
19. Incidence of dysplasia and colorectal cancer in patients with ulcerative colitis included in the Spanish ENEIDA registry
19. Tumor necrosis factor-alpha antagonists and cardiovascular disease in inflammatory bowel disease
Authors:

N. Nyboe Andersen1, C. Rungoe1, M. Andersson1, P. Munkholm2, B. Pasternak1, T. Jess1, 1Statens Serum Institut, Department of Epidemiology Research, Copenhagen, 2Herlev University Hospital, Department of Gastroenterology, Copenhagen, Denmark

2. A novel FOXO3-driven pathway determines prognosis in Crohn's disease, rheumatoid arthritis and malaria
Authors:

J. Lee1, M. Espeli1, C. Anderson2, M. Linterman1, J. Pocock1, R. Roberts3, S. Viatte4, N. Peshu5, T.T. Hien6, N.H. Phu6, E. Wesley7, C. Edwards8, T. Ahmad7, J. Mansfield9, R. Gearry3, S. Dunstan10, T. Williams5, A. Barton4, M. Parkes1, P. Lyons1, K. Smith1, 1University of Cambridge, Department of Medicine, Cambridge, 2Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 3University of Otago, Department of Medicine, Christchurch, New Zealand, 4University of Manchester, United Kingdom, 5Kenya Medical Research Institute, Kenya, 6The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam, 7Royal Devon and Exeter Hospital, United Kingdom, 8Torbay Hospital, United Kingdom, 9Newcastle University, United Kingdom, 10University of Oxford, United Kingdom

2. Gene expression profiling in CD8 T cells predicts disease course in Crohn's disease and ulcerative colitis
20. Mortality and causes of death in ulcerative colitis: results from a Norwegian population based study during a twenty years period of follow-up (the IBSEN study)
Authors:

I.L.K. Monstad1, O. Hovde2, M. Cvancarova3, I.C. Solberg1, B. Moum1, 1Oslo University Hospital, Ullevaal, Department of Gastroenterology, Oslo, 2Innlandet hospital Trust, Gastroenterology, Gjovik, 3University of Oslo, Section for Biostatistics, Oslo, Norway

20. Risk factors for inflammatory bowel disease associated colorectal carcinoma
21. Risk of cervical dysplasia and cancer in patients with inflammatory bowel disease
Authors:

C. Rungø1, J. Simonsen2, L. Riis3, M. Frisch1, E. Langholz4, T. Jess1, 1Statens serum institute, Department of Epidemiology and Research, Copenhagen, 2Statens Serum Institute, 3Herlev Hospital, 4Gentofte Hospital, Denmark

22. When to stop therapy in Crohn's disease? Results of the EPACT-2 Update panel
Authors:

V. Pittet1, A. Schoepfer2, M. Maillard2, C. Mottet3, J.-J. Gonvers2, C. Felley4, B. Burnand1, P. Michetti4, F. Froehlich5, J.-P. Vader6, 1Institute of Social & Preventive Medicine, Healthcare Evaluation Unit, Lausanne, 2Centre Hospitalier Universitaire Vaudois, Service de gastro-entérologie et d'hépatologie, Lausanne, 3Hôpital Neuchâtelois, Service de Gastroentérologie, Neuchâtel, 4Clinique La Source, Crohn and Colitis Center, Lausanne, 5Centre Hospitalier Universitaire Vaudois / University Hospital Basel, Service de gastro-entérologie et d'hépatologie, Lausanne / Basel, 6Institute for Social and Preventive Medicine, Health care evaluation unit, Lausanne, Switzerland

3. Anti-TNF in patients with an early course of Crohn's disease – a prospective observational study in Germany
Authors:

B. Bokemeyer1, U. Helwig2, A. Stallmach3, N. Teich4, R. Halle5, M. Bläker6, A.-K. Rupf7, T. Krummenerl8, D. Hüppe9, A. Krummenerl10, M. Düffelmeyer11, S. Nikolaus12, S. Schreiber12, 1Gastroenterology Practice Minden, University Hospital of Schleswig-Holstein, Department of General Medicine, Kiel, Minden, 2Gastroenterology Practice, Oldenburg, 3University of Jena, Gastroenterology Department, Jena, 4Internistische Gemeinschaftspraxis, Leipzig, 5Gastroenterologische Gemeinschaftspraxis, Hameln, 6Gastroenterology Practice, Hamburg, 7University Hospital Mannheim, Mannheim, 8Gastroenterology Practice Minden, Münster, 9Gastroenterology Practice, Herne, 10Städtisches Krankenhaus Martha Maria, Klinik für Innere Medizin I, Halle, 11IOMTech GmbH, Berlin, 12University Hospital of Schleswig-Holstein, Department of General Medicine, Kiel, Germany

3. Crohn's disease-associated dysbiosis as a predictive factor of clinical relapse: A microbiological substudy of the GETAID-STORI cohort
4. Caspase 8 maintains epithelial cell adhesion and intestinal homeostasis in vivo through regulation of clathrin-dependent endocytosis and autophagy
Authors:

G. Pineton de Chambrun1, C. Manthey2, C. McAllister2, M. Spehlmann2, A. Till3, M. Kagnoff2, P. Desreumaux4, D. Stupack5, J. Wang5, L. Eckmann2, 1Lille University Hospital, Gastroenterology, Lille, France, 2UCSD, Medicine, La Jolla, United States, 3UCSD, Molecular biology, La jolla, United States, 4North of France University, Inserm U995, Lille, France, 5UCSD, Moores Cancer center, La Jolla, United States

4. Pro-fibrogenic action of toll-like receptor and NOD-like receptor ligands on human intestinal myofibroblasts
5. Depth of remission may not predict outcome of UC over 2 years
5. Prep1: a new player in the development of IBD-associated fibrosis
Authors:

S. D'Alessio1, A. Gandelli1, C. Correale1, E. Longobardi2, F. Blasi2, S. Danese1, 1Istituto Clinico Humanitas, Rozzano, 2IFOM-IEO Campus, Italy

6. Development of the Crohn's disease (CD) digestive damage score: the Lémann score
Authors:

B. Pariente1, J.-Y. Mary1, J.-F. Colombel2, J. Cosnes3, and the International Program to develop New Indexes in Crohn's disease (IPNIC) group, 1Saint Louis Hospital, Paris, 2University Hospital, Lille, France, 3Saint Antoine Hospital, Paris, France

6. Paediatric modification of the Montreal Classification for inflammatory bowel disease – the Paris classification
7. ER stress transcription factor Xbp1 suppresses intestinal tumourigenesis
Authors:

L. Niederreiter1, T. Fritz2, T. Adolph1, A.-M. Krismer2, F. Offner3, S. Hosomi4, M. Tomczak4, B. Enrich2, E. Sarcevic3, M. Tschurtschenthaler2, S. Kempster1, T. Iwawaki5, K. Kohno6, H. Tilg2, R. Blumberg4, A. Kaser1, 1University of Cambridge, Div of Gastroenterology & Hepatology, Dept of Medicine, Cambridge, United Kingdom, 2Innsbruck Medical University, Dept of Medicine II, Innsbruck, Austria, 3Academic Teaching Hospital Feldkirch, Dept of Pathology, Feldkirch, Austria, 4Harvard Medical School, Div of Gastroenterology, Hepatology and Endoscopy, Dept of Medicine, Brigham and Women's Hospital, Boston, United States, 5Gunma University, Advanced Scientific Research Leaders Development Unit, Gunma, Japan, 6Nara Institute of Science and Technology, Laboratory of Molecular and Cell Genetics, Nara, Japan

7. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children
8. Bronchopulmonary manifestations in inflammatory bowel diseases: A retrospective study from the GETAID [GETAID Group]
8. Characterization of the ∼40,000 patient cohort of the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC)
Authors:

C.W. Lees1, International IBD Genetics Consortium, 1Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom